[1]符国宏,王连臣,陈　旭,等.甲状腺微小乳头状癌血浆和组织circRNA-102002的表达及其临床价值[J].现代检验医学杂志,2022,37(03):53-55.[doi:10.3969/j.issn.1671-7414.2022.03.011]
　FU Guo-hong,WANG Lian-chen,CHEN Xu,et al.Expression of circRNA-102002 in Plasma and Tissues of Thyroid Micropapillary Carcinoma and Its Clinical Value[J].Journal of Modern Laboratory Medicine,2022,37(03):53-55.[doi:10.3969/j.issn.1671-7414.2022.03.011]
点击复制

甲状腺微小乳头状癌血浆和组织circRNA-102002的表达及其临床价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
53-55
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Expression of circRNA-102002 in Plasma and Tissues of Thyroid Micropapillary Carcinoma and Its Clinical Value
文章编号:
1671-7414（2022）03-053-04
作者:
符国宏; 王连臣; 陈　旭; 郑扬慈
（三亚中心医院/ 海南省第三人民医院普外科，海南三亚572000）
Author(s):
FU Guo-hong;  WANG Lian-chen;  CHEN Xu;  ZHENG Yang-ci
（Department of General Surgery，Sanya Central Hospital/Hainan Third People’s Hospital，Hainan Sanya 572000，China）
关键词:
甲状腺微小乳头状癌; 环状RNA-102002
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.011
文献标志码:
A
摘要:
目的　探讨血浆和组织环状核糖核酸（ circRNA）-102002在甲状腺微小乳头状癌（ papillary thyroid microcarcinoma，PTMC）患者中的表达及其临床价值。方法　选取三亚中心医院 2018年 1月～ 2020年 12月收治的 97例 PTMC患者，将其分为淋巴结转移组（ n=56）和无淋巴结转移组（ n=41）。另选取同期 45例体检正常者作为对照组。比较各组 circRNA-102002表达水平，应用受试者工作特征曲线（ ROC）分析 circRNA-102002对 PTMC诊断及预测淋巴结转移的价值。结果　PTMC癌组织 circRNA-102002表达水平（ 2.42±1.06）明显高于癌旁正常组织（ 0.56±0.12），差异有统计学意义（ t=17.390，P＜ 0.001）。 PTMC组血浆 circRNA-102002表达水平（ 2.08±0.93）明显高于对照组（ 0.31±0.08），差异有统计学意义（ t=15.427，P＜ 0.001）。淋巴结转移组血浆和组织 circRNA102002表达水平（ 2.95±1.17，3.46±1.51）均明显高于无淋巴结转移组（ 1.24±0.43，1.35±0.58），差异有统计学意义（ t=15.382，17.964，均 P＜ 0.001）。 ROC曲线显示，血浆和组织 circRNA-102002诊断 PTMC的最佳截断值为 1.37，1.58，其曲线下面积为 0.810（95%CI： 0.752～ 0.870）和 0.850（95%CI：0.790～ 0.907）；血浆和组织 circRNA-102002诊断 PTMC患者淋巴结转移的最佳截断值为 2.27，2.65，其曲线下面积为 0.857（95%CI：0.798～ 0.920）和 0.891（95%CI：0.834～ 0.955）。结论　 circRNA-102002在 PTMC患者中呈高表达，且与淋巴结转移有关，可作为 PTMC诊断及预测淋巴结转移的参考指标。
Abstract:
Objective　To investigate the expression of circRNA-102002 in plasma and tissue in patients with papillary microcarcinoma of thyroid (PTMC) and its clinical significance. Methods　97 patients with PTMC treated in Sanya Central Hospital from January 2018 to December 2020 were selected and divided into lymph node metastasis group (n=56) and no lymph node metastasis group (n=41). Another 45 cases of normal physical examination in the same period were selected as the control group. The expression level of circRNA-102002 in each group was compared, and the value of circRNA-102002 in the diagnosis of PTMC and lymph node metastasis were analyzed by receiver operating characteristic (ROC) curve. Results　The expression level of circRNA-102002 in PTMC tumor tissues (2.42±1.06) was significantly higher than that in adjacent normal tissues (0.56±0.12)，the difference was statistically significant （t=17.390, P ＜ 0.001）. The plasma circRNA-102002 expression level of PTMC group (2.08±0.93 ) was significantly higher than that of control group(0.31±0.08)，the difference was statistically significant（t=15.427, P ＜ 0.001）. The expression level of circRNA-102002 in plasma and tissue of the lymph node metastasis group（2.95±1.17, 3.46±1.51）were significantly higher than that of the non-lymph node metastasis group （1.24±0.43, 1.35±0.58）, the differences were statistically significant (t=15.382，17.964, all P ＜ 0.001). ROC curves showed that the optimal cut-off values of plasma and tissue circRNA-102002 for PTMC diagnosis were 1.37, 1.58, and the areas under the curve were 0.810（95%CI：0.752~0.870） and 0.850（95%CI：0.790~0.907）, respectively. The optimal cut-off values of plasma and tissue circRNA-102002 for the diagnosis of lymph node metastasis in PTMC patients were 2.27, 2.65, and the areas under the curve were 0.857（95%CI：0.798~0.920） and 0.891（95%CI：0.834~0.955） respectively. Conclusion　 circRNA-102002 was highlyexpressed in patients with PTMC and was associated with lymph node metastasis, which can be used as a reference index for the diagnosis and prediction of lymph node metastasis in PTMC.

参考文献/References:

[1] RUIZ J, R?OS A, RODR?GUEZ J M, e t a l . Incidental versus clinical diagnosis of papillary thyroid microcarcinoma. Long-term prognosis[J]. Endocrinologia Diabetes Nutricion, 2020, 67(5): 317- 325.
[2] GOODALL G J, WICKRAMASINGHE V O. RNA in cancer[J]. Nature Reviews Cancer, 2021, 21(1): 22-36.
[3] LIU Jie, ZHENG Xiong, LIU Hui. Hsa-circ-0102272 serves as a prognostic biomarker and regulates proliferation, migration and apoptosis in thyroid cancer[J]. The Journal of Gene Medicine, 2020, 22(9): e3209.
[4] ZHANG Wei, LIU Ting, LI Tianshu, et al. HsacircRNA- 102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis[J]. Cancer Gene Therapy, 2021, 28(3/4): 279-293.
[5] SAM? M T, GROSSO E, MELE C, et al. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma[J]. Endocrine, 2021, 71(1): 149-157.
[6] DING Huajie, WANG Xiaojie, LIU Huiling, et al. Higher circular RNA-0015278 correlates with absence of extrathyroidal invasion, lower pathological tumor stages, and prolonged disease-free survival in papillary thyroid carcinoma patients[J]. Journal of Clinical Laboratory Analysis, 2021, 35(7): e23819.
[7] ZHANG Yu, JIA Dongdong ,ZHANG Yifei, et al. The emerging function and clinical significance of circRNAs in thyroid cancer and autoimmune thyroid diseases[J]. International Journal of Biological Sciences, 2021, 17(7): 1731-1741.
[8] QI Ying, HE Jingni, ZHANG Ying, et al. Circular RNA hsa-circ-0001666 sponges miR-330-5p, miR- 193a-5p and miR-326, and promotes papillary thyroid carcinoma progression via upregulation of ETV4[J]. Oncology Reports, 2021, 45(4): 50.
[9] WANG Yujuan, ZONG Huafeng, ZHOU Haicheng. Circular RNA circ-0062389 modulates papillary thyroid carcinoma progression via the miR-1179/high mobility group box 1 axis[J]. Bioengineered, 2021, 12(1): 1484- 1494.
[10] GUO Min, SUN Yushuang, DING Junzhu, et al. Circular RNA profiling reveals a potential role of hsacirc- IPCEF1 in papillary thyroid carcinoma[J].Mol Med Rep 2021, 24(2): 603.
[11] GUO Dan, LI Fangyuan, ZHAO Xiaoxiao, et al. Circular RNA expression and association with the clinicopathological characteristics in papillary thyroid carcinoma[J]. Oncology Reports, 2020, 44(2): 519-532.
[12] PAN Yanhui, XU Tingting, LIU Yuanzhi, et al. Upregulated circular RNA circ-0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304[J]. Biochemical and Biophysical Research Communications, 2019, 510(2): 334-338.
[13] YANG Wenwen, BAI Chao, ZHANG Li, et al. Correlation between serum circRNA and thyroid micropapillary carcinoma with cervical lymph node metastasis[J]. Medicine, 2020, 99(47): e23255.
[14] SUN J W, QIU S, YANG J Y, et al. Hsa-circ-0124055 and hsa-circ-0101622 regulate proliferation and apoptosis in thyroid cancer and serve as prognostic and diagnostic indicators[J]. European Review for Medical and Pharmacological Sciences, 2020, 24(8): 4348-4360.
[15] MA Jingjing, KAN Zhenghua. Circular RNA circ- 0008274 enhances the malignant progression of papillary thyroid carcinoma via modulating solute carrier family 7 member 11 by sponging miR-154- 3p[J]. Endocrine Journal, 2021, 68(5): 543-552.

备注/Memo

备注/Memo:
基金项目：海南省医药卫生科研基金项目(20A200043)。
作者简介：符国宏（1971-）, 男，本科，副主任医师，主要从事临床甲状腺肿瘤研究，E-mail： fuguohong8296@163.com。
更新日期/Last Update: 1900-01-01